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Abstract 
For the collagenases PMNL-CL and FIB-CL, the presence of the N-terminal Phe79 correlates with an increase in proteolytic activity. We have 
determined the X-ray crystal structure of the recombinant Phe79-Gly”2 catalytic domain of human neutrophil collagenase (PMNL-CL, MMP-8) usin 
the recently solved model of the Met80_Gly242 form for phasing and subsequently refined it to a final crystalographic R-factor of 18.0% at 2.5 x 
resolution. The PMNL-CL catalytic domain is a spherical molecule with a flat active site cleft separating a smaller C-terminal subdomain from a 
bigger N-terminal domain, that harbours two zinc ions, namely a ‘structural’ and a ‘catalytic’ zinc, and two calcium ions. The N-terminal segment 
prior to Pros6, which is disordered in the Met*‘-Gly 242 form packs against a concave hydrophobic surface made by the C-terminal helix. The , 
N-terminal Phe79 ammonium group makes a salt link with the side chain carboxylate group of the strictly conserved AsP’~~. Stabilization of the 
catalytic site might be conferred via strong hydrogen bonds made by the adjacent, likewise strictly conserved Asp233 with the characteristic ‘Met-turn’, 
which forms the base of the active site residues. 
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1. Introduction 
Matrix metalloproteinases are a family of zinc- and 
calcium-dependent endopeptidases that exhibitit prote- 
olytic activities towards most of the constituents of the 
extracellular matrix, such as the interstitial and basement 
membranes, fibronectin or laminin. Due to their central 
role in extracellular matrix degradation, they have been 
implicated in tissue remodelling processes associated 
with mammalian growth and development and in vari- 
ous pathological conditions such as rheumatoid arthritis 
or tumor invasion [l-3]. At least nine distinct, but highly 
homologous family members have been identified, in- 
cluding the collagenase subfamily comprising the inter- 
stitial collagenase (FIB-CL, MMP-1) and the neutrophil 
collagenase (PMNL-CL, MMP-8). Each member consits 
*Corresponding authors. 
Abbreviations: MMP, matrix metalloproteinases; PMNL, polymor- 
phonuclear leucocytes; FIB, fibroblast; CL, collagenase; Tris, 
Tris(hydroxymethyl)aminomethane; MES, 2-morpholinoethane sulfo- 
nit acid; PEG, polyethylenglycol. 
of an amino-terminal propeptide (maintaining latency), 
a catalytic domain harbouring the zinc- and calcium- 
sites, and a C-terminal hemopexin like domain, which is 
important for the unique ability of FIB-CL and PMNL- 
CL to cleave collagen [3-71. 
In contrast to the FIB pro-CL, which is secreted imme- 
diately after synthesis [8], PMNL pro-CL is stored as a 
highly glycosylated protein within specific granules of 
neutrophils and can be secreted as an inactive precursor 
after initiation by inflammatory mediators [9-l 11. Con- 
version of the latent proenzyme to the active enzyme is 
a crucial step in the neutrophil-mediated initiation of 
collagenolysis during inflammatory connective tissue 
turnover. In vitro, activation cleavage initiated by pro- 
teinases, mercurials or oxidants leads in a stepwise proc- 
ess to finally active species having either Phe79, Mets0 
(Valso in case of FIB-CL) or Leu” as the N-terminal 
residue [ 10,12-l 61. Activation with stromelysin-1 (SL, 
MMP-3) gives rise to a ‘superactivated’ enzyme, which 
exhibits a significantly higher activity than either of the 
two other forms; different activation factors have been 
reported including an approximately 4- to 12-fold activ- 
ity for N-terminal Phe79 FIB-CL [ 14,17-l 81 and approx- 
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imately 3.5-fold activity for N-terminal Phe79 PMNL-CL 
[16], respectively. It has been shown, that the predomi- 
nant species upon stromelysin activation is the Phe79 
form, demonstrating that ‘superactivity’ is linked with 
this form [14,16]. The structural basis of this phenome- 
non has been unclear until now. Recently, we described 
the X-ray crystal structure of Metso-Gly242 catalytic do- 
main of human PMNL-CL [19] at 2.0 A resolution. In 
this structure the N-terminal hexapeptide Met*‘-Leu- 
Thr-Pro-Gly-Asn85 was disordered; electron density was 
only observed from Pros6 onwards. Here we present he 
2.5 A X-ray crystal structure of Phe79-Gly242 catalytic 
domain of human PMNL-CL, where the N terminus is 
well ordered, and discuss the phenomenon of ‘superacti- 
vation’ in the light of this structure. 
2. Experimental 
2.1. PuriJication of the N-terminal Phe79 catalytic domain of human 
PMNL-CL 
A C-terminally truncated short form of PMNL-CL lacking the he- 
mopexin-like domain was expressed in E. coli and refolded as previ- 
ously described [5]. The latent, C-terminally truncated enzyme was 
activated by addition of active, recombinant Stromelysin-1 to a final 
concentration of 0.2pM and incubated at 37” C for 16 h. The activated 
enzyme, i.e. the catalytic domain of PMNL-CL (Phe79-Gly242), was 
afterwards purified to homogeneity by hydroxamate affinity chroma- 
tography [S]. The identity of the N-terminal Phe” was confirmed by 
amino-terminal sequence determination. 
2.2. Crystallization 
Hanging droplets were made by mixing 1.5 ,~l protein solution (-12 
mg/ml protein in 5 mM CaCl,. 100 mM NaCl, 3 mM MES/NaOH, 
0.02% NaN,, pH 6.0) 2 ,~l inhibitor solution (50 mM Pro-Leu-Gly- 
NHOH [20]) and 6 ~1 PEG- solution (10% (m/v) PEG 6000, 0.2 M 
MESINaOH, 0.02% NaN,, pH 6.0). PMNL-CL catalytic domain was 
crystallized by vapour diffusion at 22°C against 1 M potassium phos- 
phate buffer, 0.02% NaN,, pH 6.0. Small crystals of approximately 
0.5 x 0.06 x 0.03 mm were obtained within 3 days. They were harvested 
into 20% (m/v) PEG 6000, 500 mM NaCl, 100 mM CaCl , 0.1 M 
MES/NaOH, 0.02% NaN,, pH 6.0 and diffract to at least 2.5 a resolu- 
tion. The crystals belong to the orthorhombic space group P2,2,2, 
having the lattice constants a = 33.21, b = 69.53, c = 72.54 A, 
u = B = y = 90”. The asymmetric unit contains a monomer. 
2.3. Structure analysis 
X-ray measurements were done on a MAR image plate area detector 
(MAR Research, Hamburg) mounted on a Rigaku rotating anode 
X-ray generator (a = 1.5418 A, operated at 5.4 kW). X-ray intensities 
were evaluated with the MOSFLM program package [21] and loaded 
to the PROTEIN program package [22]. Data collection statistics are 
given in Table 1. A 2 F,-F, electron density map was calculated using 
the model the of Met80-GLy242 form of PMNL-CL [19] for phasing. The 
N-terminal sequence Phe79-Met-I_eu-Thr-Pro-Gly-Asn*s [23] was un- 
ambiguously defined in the electron density map and was incorporated 
using the interactive graphics program FRODO 1241. The model was 
subjected to reciprocal space least squares refinement with energy con- 
straints as implemented in X-PLOR [25] using force field parameters 
derived by Engh and Huber [26]. The final refinement statistics are 
shown in Table 2. 
3. Results 
The X-ray crystal structure of the Phe79-Gly242 cata- 
lytic domain of human PMNL-CL in complex with the 
inhibitor Pro-Leu-Gly-NHOH has been solved at 2.5 A 
resolution using the Met80-Gly242 form for phasing and 
subsequently refined to convergence at a final crystallo- 
graphic R-factor of 18.0% using all data (I > 0 o(I)) from 
8.0 to 2.5 8, resolution. The overall structure of the 
Phe79-Gly242 form as well as inhibitor binding are almost 
identical to that of the Met80-Gly242 form, which has 
been previously described in detail [19]. For the reader’s 
convenience we will briefly summarize the main aspects; 
the catalytic domain of human PMNL-CL consists of an 
N-terminal main domain and a C-terminal small domain 
separated by a relatively flat active-site cleft (as shown 
in Fig. 1). The main domain comprises a central, highly 
twisted five-stranded p-sheet, flanked by an S-shaped 
double loop and two other bridging loops on its convex 
side and by two long a-helices on its concave side, respec- 
tively (for secondary structure elements ee Table 3). It 
Fig. 1. Structure of the Phe79~Gly”* catalytic domain of human PMNL-collagenase shown as a ribbon model (using the program RIBBON (311; 
modified by A. Karshikoff). An upper (N-terminal) and a lower (C-terminal) domain are separated by a moderately deep-active site cleft. The upper 
domain harbours two zinc ions (displayed as spheres with the coordinating ligands), the ‘structural’ zinc (Zn%*, on the top, coordinated by three 
histidines and an aspartate) and the ‘catalytic’ zinc (Zn 999, in the middle, coordinated by three histidines and the inhibitor’s hydroxamic moiety (thick 
lines)), and two calcium ions (Ka TX Ka997 displayed as spheres without coordinating ligands). , , 
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Fig. 2 (a) Detailed model of the N terminus of Phe79-Gly”2 catalytic domain of human PMNL-collagenase including the N terminus (Phe79-Trp88), 
B-strand 4 and 5 (Ala’6’-Phe’76), the active site helix CZB and the extended element follwing ccB which contains the third zinc-liganding Hi?’ 
(His’97-Se?‘8), the ‘Met-turn’ (Ala2’3-Ty?‘6), the ‘catalytic’ zinc ion (displayed as a sphere), the inhibitor H,N-Pro-Leu-Gly-NHOH, and the 
C-terminal helix aC (Gln23’-Gly”2). (b) Final 2F,-F, electron density map of the N terminus with the model of the residues Phe79-Pro86, A~p~‘*-Asp~~~, 
and two solvent molecules overlayed. The contour level is 1 .O cr. 
harbours two zinc ions, referred to hereafter as the ‘cata- 
lytic’ zinc (ZnW9), and the extremely tight bound ‘struc- 
tural’ zinc ion (Zn998), and two calcium ions (Ka996, 
KaW7). The ‘catalytic’ zinc is situated at the bottom of the 
active-site cleft and is coordinated by the three His-resi- 
dues of the His’97-Glu’g8-X-X-HisZo’-X-X-Gly2W-X-X- 
His207 zinc-binding consensus equence and by the inhib- 
itor’s hydroxamic acid moiety. The ‘structural’ zinc ion 
and Ka997 are sandwiched between the surface S-shaped 
double loop and the surface of the B-sheet; Zng98 is tetra- 
hedrally coordinated by His’47, Asp14’, His’62 and His175, 
while Ka997 is octahedrally coordinated by Aspls4, Glyls5, 
AsrP7, Ile15’, Apples, and G1ui8’. The second calcium ion 
is located on the convex side of the /I-sheet at the end of 
230 I? Reinemer et al. IFEBS Letters 338 (1994) 227-233 
Table 1 
Statistics of data collection 
Table 2 
Final refinement statistics 
Number of measurements 
Number of observations 
Number of unique reflections (I > 0 a(I) 
Completeness of data (%) 
20139 
19441 
5804 
m-2.50 A 93.5 
2562.50 A 84.1 
R ’ Merge 0.125 
R sym2 0.072 
Resolution range (A) 8.0-2.5 
Number of unique data in resolution range 5683 
Total number of protein atoms (excluding H) 1317 
Solvent atoms (excluding H) 108 
R-factor’ 
8.G2.5 A 0.180 
2.55-2.50 8, 0.233 
Root-mean-square deviations from target values 
’ &I,,, = ZJ, (]Z(h,i) - < Z(h) 1 ])/&C, Z(h,i), where Z(h,i) is the inten- 
sity value of the i-th measurement ofh and c I(h) > is the corresponding 
mean value of h for all i measurements of h: the summation is over all 
measurements 
’ Rs,, = z (]Zr - < Z, > 1)/C IF, where Zr is the averaged value of point 
group related reflections and < Z, > is the averaged value of a Bijvoet 
pair 
Bonds (A) 0.012 
Angles (“) 1.7 
1 R = (ZJF, - FJ)/ZF, 
a glycine-rich open loop and is also octahedrally coordi- 
nated by AsP’~~, G~Y’~~, Gly17’, AsplT3, and by two sol- 
vent molecules. The small C-terminal domain exhibits a 
largely irregular folding, with a wide right-handed loop 
followed by an a-helix. The loop is stabilized by a tight 
1,Cturn Ala213-Leu-Met-Ty?16 known as the ‘Met-turn’ 
[27-281, aconserved topological element in the ‘metzink- 
ins’ [28] providing a hydrophobic base for the ‘catalytic’ 
zinc ion and the three His residues. 
The inhibitor lies antiparallel to the edge strand Cg4), 
with Pro” residing in a hydrophobic groove formed by 
the side chains of His162, Phe’@ and Serlsl; Leu12 forms 
two inter-main chain hydrogen bonds to Ala’63, and its 
side chain is situated in a small opening lined by His2”, 
Ala206 and His 207 while Gly-NHOH13 is oriented to- 
wards Glu”’ with he carbonyl oxygen and the hydroxyl 
oxygen complexing the ‘catalytic’ zinc (see Figs. 1 and 
2a). 
A remarkable feature in the structure of Met80-Gly242 
catalytic domain of human PMNL-CL is the concave 
surface at the bottom of the molecule, located between 
Pros6 and Ser209 and formed by the C-terminal helix OC 
and the strand following helix olB. The structure of the 
Phe79-variant reveals that the N-terminal heptapeptide 
segement Phe79-Met-Leu-Thr-Pro-Gly-Asn85 binds to 
this region (see Fig. 2a for model and Fig. 2b for electron 
density map). The N terminus extends backwards from 
the N-terminal residue of /?l (Asn9’) in a loop towards 
the active site cleft with the side chain of Trps8 slotting 
into a hydrophobic groove formed by the side chains of 
Leu93 (j?l), Ile13’ (/?3), Pro ‘M G~Y’~~ (both situated in the , 
loop connecting 84 to /?5) and Leu203 (situated at the 
C-terminal end of olB), respectively, thereby stabilizing 
the loop. It extends to Pros6 which is situated near Gly204, 
i.e. next to the active-site helix aB (left to aB in Figs. 1 
and 2a). The chain adopts a 1,Ctight turn Thrs2-Pro- 
Gly-Asn”, with the side chain of Thrs2 fitting into a small 
hydrophobic groove lined by Pros6, Gln”j5, Gly204 and 
Ala206 and pointing towards the inhibitor’s Leu (12) moi- 
ety. N-terminal to Thrs2 the chain turns downward to the 
C-terminal helix aC, crossing over with the strand fol- 
lowing helix cxB at residue Leu205 to form the only regular 
inter main chain hydrogen bond. The N-terminal ammo- 
nium group (of Phe79) forms a salt bridge with the car- 
boxylate moiety of the strictly conserved residue Asp232 
(Fig. 2a,b). The side chains of Leu” and Phe79 are ori- 
ented towards the C-terminal helix with the former pack- 
ing against the side chains of Ile240 (aC) and Asns5 and 
the latter packing against G1y236 (which is strictly con- 
served) and Ala 239 of the C-terminal helix aC, while the 
side chain of Mets0 points towards the bulk solvent and 
seems to be disordered, as no significant electron density 
could be observed for this residue. Interestingly, the N 
terminus locks two water molecules in a cavity, which is 
created by the C-terminal helix and the strand following 
the active-site helix and lined by the side chains of Va1205, 
Trp”‘, Met215, Asp232, Asp233 and G1y236, respectively. 
Both internal solvent molecules are hydrogen bonded to 
Asp233 Og’ and to Mets0 NH (Fig. 2a,b). 
4. Discussion 
Activation studies of latent pro-FIB-CL and pro- 
PMNL-CL show that species activated with stromelysin- 
Fig. 3. Truncated C,-representations of Astacin [29-301 (top), the catalytic domain of human PMNL-collagenase (middle), and Adamalysin II [27] 
(bottom) showing the structure of the N terminus and the main structure lements creating its environment @l, /l3,84, g5, the elements containing 
the ‘catalytic’ zinc signature, the C-terminal helix olC, and the ‘catalytic’ zinc ions with their liganding histidines). The N-terminal structures (Astacin: 
completely buried; PMNL-CL: packed but not buried; Adamalysin II: freely exposed) are related to their role in the enzymatic active species (see 
section 4 for details). 
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1 have a significantly higher proteolytic activity than 
species activated by other procedures [14,1618]. How- 
ever, although significant, the activity differences are 
rather small. Using collagen as substrate activity en- 
hancement factors of about 12 [17], 5-8 [ 181 and 4-6.5 
[14] have been derived for full-length FIB-CL. For full- 
length PMNL-CL they are approximately 2 and 3.5 
using a synthetic octapeptide and collagen as substrate, 
respectively [ 161. This phenomenon has been termed ‘su- 
peractivation’ [3], and it has been demonstrated that it 
is only observed with species having Phe79 as N-terminal 
residue of the active form [14,16181. 
A superposition of the structural models of the Phe79- 
G1y242 form and of the Met80-Gly242 form of human 
PMNL-CL (not shown, rms-deviation is 0.178 A for all 
atoms) reveals that both molecules uperimpose well and 
that, in particular, the geometry of the active-site resi- 
dues remains unchanged. As expected from the moderate 
observed enhancement factors, the ‘superactivation’ 
would not seem to be related to (or caused by) a visible 
structural reorientation in the active site. The significant 
disorder-order transition of the N-terminal segment 
must in some way be linked to activity enhancement. The 
formation of the salt-link between the N-terminal ammo- 
nium group and the side chain of Asp232 seems to be the 
main triggering effect on the active site, requiring an N 
terminus of correct length (including residue 79). 
The two structures (i.e. the Phe79-Gly242 and the 
Met80-Gly242 catalytic domain) show no obvious differ- 
ences in position and rigidity of the active-site residues; 
dynamic aspects beyond the accuracy of the models may 
nevertheless be important. The differences might reside 
in very tiny structural (motional) differences leading to 
stabilization of the active site and hence of the transition 
states. Alternatively, the reduced activity of N-terminally 
truncated forms could be caused by interference of the 
mobile N-terminal segment with a peptide substrate to 
be bound. 
These findings are in good agreement with the results 
of the activity studies mentioned above, and explain that 
Asp232 is strictly conserved in collagenases [3]. Another 
strictly conserved residue is G~Y’~~, positioned one turn 
away from Asp 232 in the C-terminal helix. This residue 
serves as a contact site for the side chain of residue 79 
(which is in almost every case aromatic, i.e. Phe or Tyr 
[3]). Any other amino acid replacing it would cause stereo- 
chemical strain by its side chain protruding towards the 
aromatic side chain of Phe79, most probably preventing 
the correct orientation of the N terminus. 
Fig. 3 shows the main secondary structure elements 
together with the N-terminal segements for PMNL-CL, 
astacin [29-301 and adamalysin II [27], the latter serving 
as examples for two other important subfamilies of the 
‘metzinkins’ [28]. It is interesting to compare the N-ter- 
minal structures and relate them to the role of the N 
terminus for activation of the latent proenzyme. In 
Table 3 
Secondary structure lements of the catalytic domain of human PMNL- 
CL 1321 
Structural element Residues 
Bl 92-97 
UA 106121 
;: 1277130 388 43
; 160-163 74 77
aB 191-202 
aC 23 l-240 
PMNL-CL (Fig. 3, middle) the N terminus packs against 
the C-terminal helix and the extended chain element 
Gly2”-Ser209, i.e. the N terminus is packed but not bur- 
ied. In astacin (Fig. 3, top) the N terminus is arranged 
in a topologically similar manner but is completely bur- 
ied in a groove shielded from the bulk solvent by a wide 
loop element extending from Asn12’ to Tyr’49. The am- 
monium group of its N-terminal residue (Ala’) forms a 
solvent mediated salt bridge to G1ulo3, the residue that 
immediately follows the third zinc-liganding histidine. 
Interestingly, while the position of the N terminus is 
somewhat similar to that in PMNL-CL, the position of 
the C-terminal helix is considerably shifted. This is quite 
different from the situation in adamalysin II (Fig. 3, 
bottom), where the N terminus is much shorter and is 
freely exposed, while the C-terminal helix is positioned 
quite similar to that in PMNL-CL, even though the C 
terminus extends much further and reaches up to the 
B-sheet. 
Thus, the collagenases occupy an intermediate posi- 
tion between the astacins and the adamalysins with re- 
spect to the orientation of the N terminus: in the astacins 
the N terminus is entirely buried, while it is packed but 
not buried in the collagenases and freely exposed in the 
adamalysins. This relates to the role of the N terminus 
in the enzymatic active species. In the astacins an active 
conformation would seem to require a precisely proc- 
essed N terminus; N-terminally elongated molecules pre- 
sumably adopt a different (and possibly inactive) confor- 
mation. For the collagenases, it has been demonstrated 
that the correct processing of the N terminus is not essen- 
tial but nevertheless important for maximal enzymatic 
activity. Finally, for the adamalysins it is quite clear that 
the N terminus most likely has no effect on the enzymatic 
activity. 
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